ARISE试验中脓毒性休克患者使用血管升压药的 incidence、患者特征、给药方式与结局
本研究基于ARISE试验(1,588例脓毒性休克患者)数据,描述血管升压药使用情况并探讨起始时间与90天死亡率的关系。1,102例(69%)接受血管升压药,中位起始时间4.4小时,38%在中心静脉通路建立前给药,起始前中位静脉液体量3.1 L。年龄增长和液体量增加与较早启动(4小时内)可能性降低相关,病情严重度增加与较早启动可能性升高相关(P<0.001)。在90天内死亡者中,调整年龄、APACHE II评分、研究组、纳入标准、乳酸、血管升压药前静脉液体、研究机构和感染部位后,起始血管升压药的亚风险比为1.4(95%CI 1.20-1.68,P<0.001),即较早启动与更高的粗率和调整后90天死亡率相关。
要点
- ARISE试验中69%(1,102/1,588)脓毒性休克患者在急诊就诊后接受血管升压药(去甲肾上腺素、肾上腺素、间羟胺或血管加压素)。
- 急诊就诊至启动血管升压药的中位时间为4.4小时(IQR 2.7-7.1),38%在建立中心静脉通路前即开始给药。
- 启动血管升压药前的中位静脉液体量为3.1 L(IQR 2.3-4.3)。
- 年龄增长和静脉液体量增加与4小时内早期启动血管升压药的可能性降低相关,病情严重度增加与早期启动可能性升高相关(P<0.001)。
- 在90天内死亡者中,调整年龄、APACHE II评分、研究组、纳入标准、乳酸、血管升压药前静脉液体、研究机构和感染部位后,启动血管升压药的亚风险比为1.4(95%CI 1.20-1.68,P<0.001),较早启动与更高的90天死亡率相关。
适用人群与场景
- ARISE试验纳入的脓毒性休克患者,共1,588例;其中1,102例(69%)在急诊就诊后接受血管升压药。
处置流程与药物剂量
- 血管活性药物包括去甲肾上腺素、肾上腺素、间羟胺或血管加压素。
- 急诊就诊至启动血管升压药的中位时间为4.4小时(IQR 2.7-7.1)。
- 38%的患者在建立中心静脉通路前开始血管升压药。
- 启动血管升压药前的中位静脉液体量为3.1 L(IQR 2.3-4.3)。
研究设计与关键结果
- 研究类型为对ARISE试验的二次分析,样本量1,588例,其中1,102例(69%)接受血管升压药。
- 主要暴露变量为急诊就诊后血管升压药使用;采用时间-事件分析、多变量logistic回归和倾向匹配治疗效应模型评估血管升压药起始时间与90天死亡率的关联。
- 年龄增长和静脉液体量增加与4小时内早期启动血管升压药的可能性降低相关,病情严重度增加与早期启动可能性升高相关,P<0.001。
- 在90天内死亡者中,调整年龄、APACHE II评分、研究组、纳入标准、血浆乳酸、血管升压药前静脉液体、研究机构和感染部位后,启动血管升压药的亚风险比为1.4(95%CI 1.20-1.68),P<0.001。
- 较早启动血管升压药与更高的粗率和调整后90天死亡率相关。
证据类型、等级与局限
- 证据类型:对ARISE试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: To describe the utilization of vasopressors (VP) in patients enrolled in the Australasian Resuscitation In Sepsis Evaluation (ARISE) trial, and to explore the association between time to VP and 90-day mortality.
METHODS: The primary exposure variable was VP use after arrival in the emergency department (ED). Vasoactive agents considered as VP included: norepinephrine, epinephrine, metaraminol, or vasopressin. Time-to-event analysis, multivariable logistic regression, and propensity-matched treatment effects modeling were used to assess the association between time to VP and 90-day mortality.
RESULTS: In total 1,102 of 1,588 patients (69%) in ARISE received VP at any point. The median [interquartile range (IQR)] time from ED presentation to commencing VP was 4.4 [2.7, 7.1] h, and 38% did so prior to central venous access. The median [IQR] volume of intravenous (i.v.) fluid administered prior to commencing VP was 3.1 [2.3, 4.3] L. Increasing age and volume of i.v. fluid therapy were associated with a lower likelihood of commencing VP early (within 4 h of ED presentation), while greater illness severity was associated with a higher likelihood, P < 0.001, respectively. In those who subsequently died within 90 days, the sub-hazard ratio (95% confidence interval) for commencing VP was 1.4 (1.20, 1.68), P < 0.001, adjusted for age, acute physiology and chronic health evaluation II score, study group, inclusion criteria, plasma lactate, i.v. fluid prior to VP, study institution, and site of infection.
DISCUSSION: 50% of the ARISE cohort commenced VP within 4.4 h of ED presentation, and many did so prior to central venous access. Earlier initiation of VP was associated with greater crude and adjusted 90-day mortality.
参考来源
- Udy AA, Finnis M, Jones D, et al. Incidence, Patient Characteristics, Mode of Drug Delivery, and Outcomes of Septic Shock Patients Treated With Vasopressors in the Arise Trial. Shock. 2019. PMID: 30379749. doi:10.1097/SHK.0000000000001281
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。